DreaMed key facts
- Developer of a diabetes management system designed to optimize intensive insulin therapy.
- It has raised $9.5M; the latest was Later Stage VC ($3.0M) in Aug 2024.
- Notable investors include OurCrowd, The Leona M. and Harry B. Helmsley Charitable Trust, Roman Abramovich, A-Labs, Mark Suss — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch DreaMed: the Monday email on marks, rounds and moves
DreaMed funding rounds
No funding rounds for DreaMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
DreaMed investors
10 investors are on record for DreaMed, including OurCrowd, The Leona M. and Harry B. Helmsley Charitable Trust, Roman Abramovich and A-Labs.
About DreaMed
Developer of a diabetes management system designed to optimize intensive insulin therapy. The company's system uses event-driven machine learning and logic technology to process multiple personalized parameters such as insulin delivery data, glucose readings, meal data, and optimized insulin dosing treatment plans, enabling care providers and patients to improve living standards and lower overall treatment costs.
- Sector
- Healthcare
- HQ
- Petah Tikva, Israel
- Founded
- 2014
- Employees
- 20
- Website
- dreamed.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
DreaMed doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.